A phase II study to assess the efficacy of osimertinib in patients with EGFR MT(+)T790M(-) NSCLC

被引：0

作者：

Hayakawa, Daisuke ^{[1
]}

Takeda, Masayuki ^{[2
,3
]}

Shimokawa, Mototsugu ^{[4
]}

Nakamura, Atsushi ^{[5
]}

Nosaki, Kaname ^{[6
]}

Watanabe, Yasutaka ^{[7
]}

Kato, Terufumi ^{[8
]}

Tanaka, Hiroshi ^{[9
]}

Takahashi, Toshiaki ^{[10
]}

Oki, Masahide ^{[11
]}

Tachihara, Motoko ^{[12
]}

Fujimoto, Daichi ^{[13
]}

Yamaguchi, Kakuhiro ^{[14
]}

Hayashi, Hidetoshi ^{[2
]}

Yamamoto, Shoichiro ^{[15
]}

Iwama, Eiji ^{[16
]}

Azuma, Koichi ^{[17
]}

Yamamoto, Nobuyuki ^{[13
]}

Nakagawa, Kazuhiko ^{[2
]}

机构：

[1] Juntendo Univ, Dept Resp Med, Grad Sch Med, Tokyo, Japan

[2] Kindai Univ, Fac Med, Dept Med Oncol, Osaka, Japan

[3] Nara Med Univ, Dept Canc Genom & Med Oncol, Kashihara, Nara, Japan

[4] Yamaguchi Univ, Dept Biostat, Grad Sch Med, Yamaguchi, Japan

[5] Sendai Kousei Hosp, Dept Pulm Med, Sendai, Miyagi, Japan

[6] Natl Canc Ctr Hosp East, Dept Thorac Oncol, Kashiwa, Chiba, Japan

[7] Saitama Canc Ctr, Div Thorac Oncol, Saitama, Japan

[8] Kanagawa Canc Ctr, Dept Thorac Oncol, Yokohama, Kanagawa, Japan

[9] Niigata Canc Ctr Hosp, Dept Internal Med, Niigata, Japan

[10] Shizuoka Canc Ctr, Div Thorac Oncol, Shizuoka, Japan

[11] Natl Hosp Org Nagoya Med Ctr, Dept Resp Med, Nagoya, Aichi, Japan

[12] Kobe Univ, Grad Sch, Dept Internal Med, Div Resp Med, Kobe, Hyogo, Japan

[13] Wakayama Med Univ, Internal Med 3, Wakayama, Japan

[14] Hiroshima Univ Hosp, Dept Resp Med, Hiroshima, Japan

[15] Ehime Univ, Grad Sch Med, Dept Cardiol Pulmonol Hypertens & Nephr, Ehime, Japan

[16] Kyushu Univ, Dept Resp Med, Grad Sch Med Sci, Fukuoka, Japan

[17] Kurume Univ, Sch Med, Div Respirol Neurol & Rheumatol, Dept Internal Med, Kurume, Fukuoka, Japan

[18] Japan Lung Canc Alliance, Yokohama, Kanagawa, Japan

来源：

ANNALS OF ONCOLOGY | 2023年 / 34卷

关键词：

D O I：

10.1016/j.annonc.2023.09.128

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

O7-2

引用

页码：S1387 / S1387

页数：1

共 50 条

[21] Osimertinib beyond disease progression in T790M EGFR-positive NSCLC patients: a multicenter study of clinicians' attitudes
Cortellini, A.
Leonetti, A.
Catino, A.
Pizzutillo, P.
Ricciuti, B.
De Giglio, A.
Chiari, R.
Bordi, P.
Santini, D.
Giusti, R.
De Tursi, M.
Brocco, D.
Zoratto, F.
Rastelli, F.
Citarella, F.
Russano, M.
Filetti, M.
Marchetti, P.
Berardi, R.
Torniai, M.
Cortinovis, D.
Sala, E.
Maggioni, C.
Follador, A.
Macerelli, M.
Nigro, O.
Tuzi, A.
Iacono, D.
Migliorino, M. R.
Banna, G.
Porzio, G.
Cannita, K.
Ferrara, M. G.
Bria, E.
Galetta, D.
Ficorella, C.
Tiseo, M.
CLINICAL & TRANSLATIONAL ONCOLOGY, 2020, 22 (06): : 844 - 851
[22] Osimertinib beyond disease progression in T790M EGFR-positive NSCLC patients: a multicenter study of clinicians’ attitudes
A. Cortellini
A. Leonetti
A. Catino
P. Pizzutillo
B. Ricciuti
A. De Giglio
R. Chiari
P. Bordi
D. Santini
R. Giusti
M. De Tursi
D. Brocco
F. Zoratto
F. Rastelli
F. Citarella
M. Russano
M. Filetti
P. Marchetti
R. Berardi
M. Torniai
D. Cortinovis
E. Sala
C. Maggioni
A. Follador
M. Macerelli
O. Nigro
A. Tuzi
D. Iacono
M. R. Migliorino
G. Banna
G. Porzio
K. Cannita
M. G. Ferrara
E. Bria
D. Galetta
C. Ficorella
M. Tiseo
Clinical and Translational Oncology, 2020, 22 : 844 - 851
[23] Osimertinib plus anlotinib for advanced NSCLC with acquired EGFR T790M mutation: results from a multicenter phase II study with ctDNA analysis
Xinyue Wang
Zhaona Li
Liuchun Wang
Yan Liang
Chun Huang
Peng Chen
Dingzhi Huang
Xia Song
Cuimin Ding
Changli Wang
Richeng Jiang
BMC Medicine, 23 (1)
[24] Analysis of resistance mechanisms to osimertinib in patients with EGFR T790M advanced NSCLC from the AURA3 study
Papadimitrakopoulou, V. A.
Wu, Y-L.
Han, J-Y.
Ahn, M-J.
Ramalingam, S. S.
John, T.
Okamoto, I.
Yang, J. C-H.
Bulusu, K. C.
Laus, G.
Collins, B.
Barrett, J. C.
Chmielecki, J.
Mok, T. S. K.
ANNALS OF ONCOLOGY, 2018, 29 : 741 - 741
[25] Clinical Outcomes of Patients with EGFR T790M+NSCLC on Osimertinib
Tan, W. L.
Hennedige, T. P.
Ng, Q. S.
Tan, S. H.
Tran, N. T. A.
Chua, B. J. G.
Toh, C. K.
Tan, E. H.
Tan, D.
Ang, M.
Kanesvaran, R.
Jain, A.
Lim, T. K. H.
Gogna, A.
Koh, M.
Yip, C. S. P.
Thng, C. H.
Chowbay, B.
Tan, M. H.
Lim, W.
JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2206 - S2206
[26] Osimertinib Depletes EGFR T790M in the Spinal Fluid of Patients with Carcinomatous Meningitis of Lung Adenocarcinoma Harboring De Novo EGFR T790M
Senoo, Satoru
Ohashi, Kadoaki
Nishii, Kazuya
Hara, Naofumi
Kano, Hirohisa
Ninomiya, Kiichiro
Maeda, Yoshinobu
Kiura, Katsuyuki
JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (08) : E140 - E142
[27] EGFR T790M resistance mutation in NSCLC: Real-life data of patients treated with osimertinib.
Hochmair, Maximilian J.
Holzer, Sophia
Filipits, Martin
Mohn-Staudner, Andrea
Arns, Madeleine
Errhalt, Peter
Absenger, Gudrun
Koller-Herzog, Ursula
Setinek, Ulrike
Haslbauer, Ferdinand
Korger, Mark A.
Patocka, Kurt
Kolb, Rainer
Burghuber, Otto
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[28] EGFR T790M Resistance Mutation in NSCLC: Real-Life Data of Austrian Patients Treated with Osimertinib
Hochmair, Maximilian
Holzer, Sophia
Filipits, Martin
Mohn-Staudner, Andrea
Errhalt, Peter
Absenger, Gudrun
Bundalo, Tatjana
Arns, Madeleine
Setinek, Ulrike
Mikes, Romana
Kolb, Rainer
Schumacher, Michael
Zoechbauer-Mueller, Sabine
Patocka, Kurt
Haslbauer, Ferdinand
Rudzki, Jakob
Burghuber, Otto
JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1254 - S1254
[29] Intracranial Activity of Osimertinib in Naive EGFRm T790M(-) And Treated EGFRm T790M(+) NSCLC Patients with Asymptomatic Brain Metastases
Peled, N.
Nechushtan, H.
Ilouze, M.
Dudnik, E.
Inbar, E.
JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2223 - S2223
[30] ASTRIS a RWT with Osimertinib in NSCLC EGFR T790M Mutated: Disease Characteristics from Patients Included in Argentina
Biolchi, M.
Recondo, G.
Casalnuovo, M.
Tsou, F.
Diaz Perez, I.
Reinhold, F.
Martin, C.
JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (09) : S169 - S169

← 1 2 3 4 5 →